Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial

Benzinga05:33

Express News | Merck & Co Inc - Patients in Keyform-008 Trial May Continue Therapy Until Study Completion

Breakings05:30

Express News | Merck & Co Inc - Discontinues Clinical Development Programs for Vibostolimab and Favezelimab

Breakings05:30

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations With Pembrolizumab

Businesswire05:30

Express News | Merck Provides Update on Keyvibe and Keyform Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations With Pembrolizumab

Breakings05:30

Dow's 115-Point Rally Highlighted By Gains In Honeywell, Nike Shares

MarketWatchDec 16 23:08